ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2022
Stage Migration and Lung Cancer Incidence After Initiation of Low-Dose Computed Tomography Screening.
Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 66 citations in OpenAlex.
- Incidence and mortality trends after introduction of lung cancer screening in a community-based healthcare system.Cancer epidemiology · 2026Article
- Narrative review of the staging classification controversy in stage N3 small cell lung cancer: from the perspective of overlapping Veterans Administration Lung Study Group and International Association for the Study of Lung Cancer definitions.Journal of thoracic disease · 2026Review
- Balancing diagnostic approach and oncologic risk in surgically resected lung cancer: propensity-matched analysis of intraoperative versus percutaneous biopsy by tumor location and morphology.International journal of surgery (London, England) · 2026Article
- Increased rates of surgical resection of early-stage small cell lung cancer in a single-institution cohort.Journal of thoracic disease · 2026Article
- Article
- Article
- Maximum standardized uptake (SUVmax) is associated with pathologically upstaged and recurrence-free survival in non-small cell lung cancer after curative surgery.World journal of surgical oncology · 2026Article
- East-West Disparities in Lung Cancer Screening: Subsolid Nodule Prevalence, Interval Growth, and Decision-Making Analysis.Diagnostics (Basel, Switzerland) · 2026Review
- Article
- Real-world trends in diagnosis, treatment, and survival of non-small cell lung cancer in Vietnam.BMC cancer · 2026Observational
- Analysis of Risk Factors for Ipsilateral Shoulder Pain and Pain Intensity After Thoracic Surgery.Pain research & management · 2026Article
- Editorial: Advancing diagnostic excellence in early lung cancer detection.Frontiers in oncology · 2026Article
- Rising burden of early-onset lung cancer among Chinese adolescents and young adults (1990-2023): a Bayesian age-period-cohort analysis with projections to 2038.Frontiers in medicine · 2026Article
- Article
- Machine Learning Models Using General and Tissue-Specific Feature Extractors for Accurate Subtyping of Biopsy Samples: Advancing Lung Cancer Diagnosis in Latin America.JTO clinical and research reports · 2025Article
- Understanding East-West differences in subsolid nodules: prevalence and overdiagnosis implications in lung cancer screening.Annals of medicine · 2025Article
- Employment of artificial intelligence for early lung cancer diagnosis: a retrospective cohort study.BMJ open respiratory research · 2025Article
- Lung Cancer Outcomes in Vietnam: A 6-Year Retrospective Study.Journal of immunotherapy and precision oncology · 2025Article
- Patterns of Medical Care Cost by Service Type Associated With Lung Cancer Screening.Medical care · 2025Article
- Proteomic Analysis of Extracellular Vesicles Identifies CDCP1 as Critical Metastasis-Related Glycoprotein in Lung Cancer.Journal of extracellular vesicles · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
introductionDespite evidence from clinical trials of favorable shifts in cancer stage and improvements in lung cancer-specific mortality, the effectiveness of lung cancer screening (LCS) in clinical practice has not been clearly revealed.
methodsWe performed a multicenter cohort study of patients diagnosed with a primary lung cancer between January 1, 2014, and September 30, 2019, at one of four U.S. health care systems. The primary outcome variables were cancer stage distribution and annual age-adjusted lung cancer incidence. The primary exposure variable was receipt of at least one low-dose computed tomography for LCS before cancer diagnosis.
resultsA total of 3678 individuals were diagnosed with an incident lung cancer during the study period; 404 (11%) of these patients were diagnosed after initiation of LCS. As screening volume increased, the proportion of patients diagnosed with lung cancer after LCS initiation also rose from 0% in the first quartile of 2014 to 20% in the third quartile of 2019. LCS did not result in a significant change in the overall incidence of lung cancer (average annual percentage change [AAPC]: -0.8 [95% confidence interval (CI): -4.7 to 3.2]) between 2014 and 2018. Stage-specific incidence rates increased for stage I cancer (AAPC = 8.0 [95% CI: 0.8-15.7]) and declined for stage IV disease (AAPC = -6.0 [95% CI: -11.2 to -0.5]).
conclusionsImplementation of LCS at four diverse health care systems has resulted in a favorable shift to a higher incidence of stage I cancer with an associated decline in stage IV disease. Overall lung cancer incidence did not increase, suggesting a limited impact of overdiagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.